NCT07067866 Weaning Approaches for Vasopressin in Sepsis
| NCT ID | NCT07067866 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Hospital Nossa Senhora da Conceicao |
| Condition | Septic Shock |
| Study Type | INTERVENTIONAL |
| Enrollment | 82 participants |
| Start Date | 2025-10-01 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 82 participants in total. It began in 2025-10-01 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this study, we aim to evaluate the incidence of hypotension during vasopressin weaning by comparing two methods - titrated reduction versus abrupt withdrawal - through the conduct of a randomized clinical trial.
Eligibility Criteria
Inclusion Criteria: * Age over 18 years * Admitted to the Intensive Care Unit * Patients with vasopressor dependent sepsis * Receiving combined norepinephrine and vasopressin therapy Exclusion Criteria: * Withdrawal/reduction of vasopressin related to a plan of treatment limitation or palliative care * Withdrawal/reduction of vasopressin associated with the initiation of adrenaline or any other vasopressor
Contact & Investigator
Cássio Mallmann, Critical Care Physician, MS
PRINCIPAL INVESTIGATOR
Hospital Nossa Senhora da Conceicao
Frequently Asked Questions
Who can join the NCT07067866 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Septic Shock. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07067866 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 82 participants.
Is NCT07067866 currently recruiting?
Yes, NCT07067866 is actively recruiting participants. Contact the research team at wagnernedel@gmail.com for enrollment information.
Where is the NCT07067866 trial being conducted?
This trial is being conducted at Porto Alegre, Brazil.
Who is sponsoring the NCT07067866 clinical trial?
NCT07067866 is sponsored by Hospital Nossa Senhora da Conceicao. The principal investigator is Cássio Mallmann, Critical Care Physician, MS at Hospital Nossa Senhora da Conceicao. The trial plans to enroll 82 participants.